,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2019', 'fs': 'Aug 2019', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005fBfn2AE'}, 'Id': 'a0POZ000005fBfn2AE', 'Event_Date__c': '2019-08-22', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Aug 2019', 'Status_History__c': 'a132P000000AriHQAS'}, 'change': None}, {'Summary': {'s': '2019-09: Clinician application received', 'fs': '2019-09: Clinician application received', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2019', 'fs': 'Sep 2019', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005fBfo2AE'}, 'Id': 'a0POZ000005fBfo2AE', 'Event_Date__c': '2019-09-16', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Application Received', 'Summary__c': '2019-09: Clinician application received', 'Formatted_Date__c': 'Sep 2019', 'Status_History__c': 'a132P000000BsERQA0'}, 'change': None}, {'Summary': {'s': '<p>2019-10: Clinician application received</p>', 'fs': '<p>2019-10: Clinician application received</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2019', 'fs': 'Oct 2019', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005fBfp2AE'}, 'Id': 'a0POZ000005fBfp2AE', 'Event_Date__c': '2019-10-21', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Application Received', 'Summary__c': '<p>2019-10: Clinician application received</p>', 'Formatted_Date__c': 'Oct 2019', 'Status_History__c': 'a132P000000B48KQAS'}, 'change': None}, {'Summary': {'s': '2020-02: Supplier application received', 'fs': '2020-02: Supplier application received', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005fBfq2AE'}, 'Id': 'a0POZ000005fBfq2AE', 'Event_Date__c': '2020-02-29', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Application Received', 'Summary__c': '2020-02: Supplier application received', 'Formatted_Date__c': 'Feb 2020', 'Status_History__c': 'a132P000000BsEgQAK'}, 'change': None}]",Aug 2019,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2020', 'fs': 'Mar 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005fBfr2AE'}, 'Id': 'a0POZ000005fBfr2AE', 'Event_Date__c': '2020-03-20', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Mar 2020', 'Status_History__c': 'a132P000000Bb3zQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2020', 'fs': 'Jun 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005fBfs2AE'}, 'Id': 'a0POZ000005fBfs2AE', 'Event_Date__c': '2020-06-17', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2020', 'Status_History__c': 'a132P000000BsINQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2020', 'fs': 'Jun 2020', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 3 July 2020', 'fs': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 3 July 2020', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005fBft2AE'}, 'Id': 'a0POZ000005fBft2AE', 'Event_Date__c': '2020-06-18', 'Event_Description__c': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 3 July 2020', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2020', 'Status_History__c': 'a132P000000BsYbQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee <b>recommended</b> that midostaurin (up to four cycles with intensive chemotherapy, without maintenance therapy) be funded for the treatment of <i>de novo</i> acute myeloid leukaemia that is FLT3 mutation positive with a high priority within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application — only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a diagnosis of acute myeloid leukaemia; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Condition must be FMS tyrosine kinase 3 (FLT3) mutation positive; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must not have received a prior line of intensive chemotherapy for acute myeloid leukaemia; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be considered eligible for standard intensive chemotherapy; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Midostaurin to be funded for a maximum of 4 cycles.</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee noted that the supplier of midostaurin had requested funding for up to six cycles with intensive chemotherapy and funding for up to 12 cycles of maintenance therapy. However, the Subcommittee considered that the incremental benefit of six cycles of midostaurin over four cycles in combination with intensive chemotherapy was not sufficient to warrant the additional two cycles, and that the available evidence did not support a benefit of midostaurin maintenance in this patient population.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee also considered that, if PHARMAC was only able to fund one of these medicines (i.e gemtuzumab ozogamicin or midostaurin) for the treatment of patients with favourable, intermediate or undetermined risk AML, the greater clinical benefit could be obtained through first funding gemtuzumab ozogamicin, as this would result in benefits for a wider population rather than a defined subset of the population.</p><p><br></p>', 'fs': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee <b>recommended</b> that midostaurin (up to four cycles with intensive chemotherapy, without maintenance therapy) be funded for the treatment of <i>de novo</i> acute myeloid leukaemia that is FLT3 mutation positive with a high priority within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application — only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a diagnosis of acute myeloid leukaemia; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Condition must be FMS tyrosine kinase 3 (FLT3) mutation positive; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must not have received a prior line of intensive chemotherapy for acute myeloid leukaemia; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be considered eligible for standard intensive chemotherapy; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Midostaurin to be funded for a maximum of 4 cycles.</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee noted that the supplier of midostaurin had requested funding for up to six cycles with intensive chemotherapy and funding for up to 12 cycles of maintenance therapy. However, the Subcommittee considered that the incremental benefit of six cycles of midostaurin over four cycles in combination with intensive chemotherapy was not sufficient to warrant the additional two cycles, and that the available evidence did not support a benefit of midostaurin maintenance in this patient population.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee also considered that, if PHARMAC was only able to fund one of these medicines (i.e gemtuzumab ozogamicin or midostaurin) for the treatment of patients with favourable, intermediate or undetermined risk AML, the greater clinical benefit could be obtained through first funding gemtuzumab ozogamicin, as this would result in benefits for a wider population rather than a defined subset of the population.</p><p><br></p>', 'change': None}, 'Published_Discussion': {'s': '<h2>Discussion</h2><p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that acute myeloid leukaemia (AML) is a haematopoietic neoplasm involving clonal proliferation of myeloid precursor cells, leading to increased production of immature malignant cells and a reduction in mature myeloid cells. The Subcommittee noted that AML is a highly symptomatic, rapidly progressing disease that results in a variety of systemic consequences (e.g. anaemia, bleeding, and an increased risk of infection) due to bone marrow failure or the presence of AML blasts in the bone marrow, peripheral blood or other organs, with poor overall survival. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients with AML spend a substantial amount of time in hospital for disease management, treatment administration, supportive care and investigations; this inpatient duration may be weeks or months for patients who receive intensive chemotherapy. The Subcommittee noted evidence where the caregivers of patients with AML, in addition to patients themselves, experienced post-traumatic stress (<a href=""https://pubmed.ncbi.nlm.nih.gov/24673368/"" target=""_blank"">Leunis et al. Eur J Haematol. 2014;93:198-206</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/26014209/"" target=""_blank"">Jia et al. Psychooncology. 2015;24:1754-60</a>). Members considered the impact on family and whānau is due to the need to support the patient with AML through this long and difficult illness. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that AML is the most common acute leukaemia diagnosed in New Zealand adults, with incidence estimated to be 6-9 per 100,000 in the population in 2016 (<a href=""https://pubmed.ncbi.nlm.nih.gov/29860482/"" target=""_blank"">Global Burden of Disease Cancer Collaboration. JAMA Oncol. 2018;4:1553-68</a>). However, Members estimated that if AML secondary to prior haematological malignancy or previous treatment of malignant disease is excluded, the incidence of <i>de novo</i> AML in New Zealand is lower, closer to 3.5 per 100,000. The Subcommittee noted that AML incidence increases with age and that the median age at diagnosis is between 65 to 70 years. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that Māori have an increased risk of AML relative to New Zealand Caucasians (<a href=""https://pubmed.ncbi.nlm.nih.gov/15929115/"" target=""_blank"">Tracey et al. Am J Hematol. 2005;79:114-8</a>) and that Māori have reduced chances of finding suitable stem cell donors from international registries, leading to disproportionately less stem cell transplantation as part of therapy for AML.<span style=""background-color: yellow; font-size: 7pt;""> </span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that standard of care diagnostic investigation of patients with AML includes bone marrow sampling, molecular testing and immunophenotyping via flow cytometry; the latter of which would detect the cell surface antigen CD33 that is present for approximately 85–90% of patients with AML. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the health need and probability of survival for patients with AML is predominantly influenced by age and cytogenetic risk profile which can be categorised as favourable or intermediate (combined, these account for about 70% of <i>de novo</i> AML) or as adverse (~30% of cases). The Subcommittee noted that molecular testing identifies a range of genetic mutations in AML which occur in different patterns and combinations, contributing to a patient’s cytogenetic risk: </p><p style=""text-align: justify;"">1.6.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that the FLT3 (FMS-like tyrosine kinase 3) mutation occurs in about one-third of patients with AML. The Subcommittee considered that patients with FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) experience more frequent and earlier disease relapse leading to poor survival.</p><p style=""text-align: justify;"">1.6.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that patients with acute promyelocytic leukaemia (APL) have a particular, mutation, that is associated with good outcomes from current treatment, therefore patients with APL were considered out of scope for the current funding applications. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that cytogenetic testing is routinely available across New Zealand and that results are generally available within 48 to 72 hours. The Subcommittee considered it important for cytogenetic results to be available before treatment commences to ensure therapy is optimal with regard to the patient’s cytogenetics, however, unavoidable delays (e.g. due to public holidays) are known to lead to additional supportive care requirements while results are pending. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that approximately half to three-quarters of younger patients (generally defined as those aged less than 60 years) with AML are suitable for intensive induction and consolidation chemotherapy with anthracycline (e.g. daunorubicin) and cytarabine, both which are currently funded without restriction and remain the backbone of intensive treatment for AML. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that many New Zealand patients with AML have participated in UK-based clinical trials, most recently the AML-19 trial; a randomised, factorial design, open-label, phase III trial comparing several different treatment strategies (including gemtuzumab ozogamicin and midostaurin) in adults with <i>de novo</i> AML who are suitable for intensive chemotherapy. Members considered that early data from the AML-19 trial suggests an improvement in long-term survival in younger patients.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that azacitidine is not used to treat patients with AML who are deemed suitable for treatment with intensive chemotherapy. The Subcommittee considered that azacitidine is generally used in patients of older age, those who are frail, have low AML blast cell counts and have adverse cytogenetics. As a result, the Subcommittee considered that any widening of access to azacitidine for patients with AML would not affect the treatment paradigm for patients with AML who are suitable candidates for intensive chemotherapy.</p><p style=""text-align: justify;""><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that disease relapse, which is accompanied by a return of symptoms due to blast cell re-emergence, is of high unmet clinical need for patients with AML as there are limited subsequent treatment options and often very shortened survival post-relapse. The Subcommittee noted that younger patients with AML who receive intensive treatment have 5 year-survival rates of about 50% at 5 years and this rate has improved over past decades, predominantly driven by improved understanding of the disease, therapeutic approaches and molecular testing in clinical trials; however, patients over 60 have a lower rate of survival (about 25% at 5 years) and this has not improved substantially over past decades.</p><p style=""text-align: justify;""><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>Members noted that patients with AML with intermediate or adverse disease risk that is in remission after intensive chemotherapy treatment may be fit enough to undergo allogenic stem cell transplant, leading to better outcomes for such patients; however, older patients (e.g. patients over 60 years of age) may not be suitable candidates for transplant and therefore are unable to receive this additional benefit.</p><p><br></p><h2>Midostaurin</h2><p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that midostaurin is a multi-targeted kinase inhibitor that inhibits FLT3 receptor signalling, inducing cell death in leukaemic cells that express mutated FLT3 receptors and overexpressed wild-type receptors. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that midostaurin is approved by Medsafe for use in combination with standard anthracycline and cytarabine induction and cytarabine consolidation chemotherapy, followed in patients with complete response by single agent maintenance therapy for adult patients with newly diagnosed AML who are FLT3 mutation-positive. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.3. </span>The Subcommittee noted that midostaurin is available as 25 mg capsule and would be administered in combination with standard intensive chemotherapy containing anthracycline and cytarabine, with midostaurin taken orally at a dose of 50 mg twice daily on days 8 to 21 of each 21-day cycle (14 days of treatment). </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the target patient population for midostaurin (FLT3 mutation positive disease) is a subset of the target patient population for gemtuzumab ozogamicin (AML with favourable or intermediate cytogenetic risk). The Subcommittee noted that the supplier had requested midostaurin be funded for induction and consolidation therapy, and then as maintenance for twelve 28-day cycles, however, the clinician applicants had requested funding for induction and consolidation therapy only. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that the key clinical trial evidence for midostaurin comes from the phase III, randomised (1:1), double-blind, placebo-controlled multicentre RATIFY trial which included 717 patients aged 18 to 59 years with newly diagnosed, untreated AML (excluding APL) with TKD or ITD (high or low) FLT3-mutations (<a href=""https://pubmed.ncbi.nlm.nih.gov/28644114/"" target=""_blank"">Stone et al. N Engl J Med. 2017;377:454-64</a>). The Subcommittee noted that the study investigated standard induction with daunorubicin 60 mg/m<sup>2</sup>, cytarabine 200 mg/m<sup>2</sup> plus midostaurin or placebo; then standard consolidation therapy with high-dose cytarabine 3 g/m<sup>2</sup> twice daily plus midostaurin or placebo; then if in remission, maintenance midostaurin or placebo. Patients received midostaurin 50 mg orally twice daily or placebo taken for a fortnight within each 21-day treatment cycle during induction and consolidation (total of five or six cycles), then midostaurin 50 mg orally twice daily or placebo alone (according to initial randomisation) for twelve 28-day cycles during maintenance therapy. The Subcommittee noted that 36% (896) of patients screened for the RATIFY trial (3,277) had FLT3 mutations and that over half of the patients in each arm received stem cell transplant in the first line of therapy. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that the RATIFY trial reported median event-free survival (EFS) of 8.2 months (95% CI: 5.4 to 10.7) with midostaurin compared with 3.0 months (95% CI: 1.9 to 5.9) with placebo (HR for event 0.78, 95% CI: 0.66 to 0.93, P=0.002). The Subcommittee noted that the median OS in the RATIFY trial was 74.7 months (95% CI: 31.5 to not reached) with midostaurin compared with 25.6 months (95% CI: 18.6 to 42.9) with placebo (HR for death 0.78, 95% CI: 0.63 to 0.96, P=0.009). The Subcommittee considered that this evidence showed a benefit of midostaurin treatment with respect to EFS and OS in patients with AML with FLT3 mutations, and noted that subgroup analysis according to ITD or TKD status reported similar hazard ratios for OS although these were not statistically significant.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the RATIFY trial reported higher rates of grade 3 to 5 anaemia (92.7% with midostaurin compared with 87.8% with placebo, <i>P</i>=0.03) and rash (14.1% with midostaurin compared with 7.6% with placebo, <i>P</i>=0.008). Overall, the Subcommittee considered that the rates of serious adverse events (SAEs) were similar between the groups and that midostaurin was well tolerated, although tolerance was lower in patients who received midostaurin post-transplant. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.8. </span>The Subcommittee noted that the comparative evidence for midostaurin maintenance following intensive chemotherapy came from the RATIFY trial; however, RATIFY participants who received intensive chemotherapy without midostaurin were unable to cross over to receive midostaurin in the maintenance phase, therefore the trial did not provide appropriate evidence indicating additional benefit from the addition of midostaurin as maintenance. The Committee considered that there is currently limited trial evidence of benefit from midostaurin maintenance, and that the ongoing clinical trials would contribute to this understanding. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.9. </span>The Subcommittee noted evidence from the phase II, open-label, hypothesis-generating AMLSG 16-10 trial, which investigated use of midostaurin during induction (50 mg twice daily, starting on day 8, until 48 hours before the start of the subsequent chemotherapy cycle) with daunorubicin 60 mg/m<sup>2 </sup>and cytarabine<sup> </sup>200 mg/m<sup>2</sup>, in consolidation with either allogenic stem cell transplant or high-dose cytarabine 3 g/m<sup>2</sup> (<span style=""color: rgb(26, 26, 26); font-family: Helvetica, sans-serif;"">starting on day 6, until 48 hours before the start of conditioning therapy for stem cell transplant or the start of subsequent consolidation chemotherapy)</span> and as maintenance therapy (midostaurin alone, 50 mg orally twice daily for twelve 28-day cycles) in 284 patients with newly diagnosed AML (including secondary AML but excluding APL) with FLT3-ITD mutation (<a href=""https://pubmed.ncbi.nlm.nih.gov/30563875/"" target=""_blank"">Schlenk et al. Blood. 2019;133:840-51</a>). </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the AMLSG 16-10 trial allowed allogenic transplant at investigator discretion and included patients up to 70 years of age. The Subcommittee noted that the trial used historical controls from five prospective AMLSG trials of induction and consolidation, recruiting from 1993-2008, and considered that these controls were of limited quality for comparison.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that median EFS in AMLSG 16-10 was 13.2 months (95% CI: 10.0-18.3 months), and that EFS at two years was 39% (95% CI: 33-47%) in younger patients aged 18 to 60 years and 53% (95% CI: 46-61%) in older patients aged 61 to 70 years. The Subcommittee noted that median OS was 26.0 months (95% CI: 18.9-37.0 months) and that OS at 2 years was 34% (95% CI: 24-47%) in younger patients and 46% (95% CI: 35-59%) in older patients. The Subcommittee considered that midostaurin provided good outcomes for patients aged over 60.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted additional evidence provided by the supplier regarding midostaurin in AML, including the following from phase I-IIb clinical trials:</p><p style=""text-align: justify;""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/25776192/"" target=""_blank"">Cooper et al. Clin Lymphoma Myeloma Leuk. 2015;15:428-32</a> </p><p style=""text-align: justify;""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/22627678"" target=""_blank"">Stone et al. Leukaemia. 2012;26:2061-8</a> </p><p style=""text-align: justify;""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/20733134"" target=""_blank"">Fischer et al. J Clin Oncol. 2010;28:4339-45</a> </p><p style=""text-align: justify;""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/25530214"" target=""_blank"">Strati et al. Am J Hematol. 2015;90:276-81</a></p><p style=""text-align: justify;""><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee considered that approximately 88 patients with AML would be fit for intensive chemotherapy each year in New Zealand, of which approximately three-quarters (66 patients) would have favourable or intermediate cytogenetics (and would therefore be potentially suitable for gemtuzumab ozogamicin); approximately one third of those patients would have mutation in FLT3 that would make them potentially suitable for treatment with midostaurin.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee considered that midostaurin would provide a treatment benefit for the group of patients with AML with favourable or intermediate cytogenetic risk who have FLT3 mutation positive disease. The Subcommittee considered that the use of midostaurin, if funded, would not change usage of other funded medicines used to treat AML. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;""> </span>Members considered that there is no evidence to suggest that patients with AML have an unmet need for maintenance treatment after intensive chemotherapy or as a bridge to transplant, noting that transplant requires disease remission and the current evidence indicates that neither maintenance therapy or treatment used as a bridge to transplant improves remission rates in AML.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;""> </span>\xa0The Subcommittee considered that, based on the mature published evidence for midostaurin at this time, four cycles of midostaurin given with intensive chemotherapy would provide sufficient survival benefit compared with six cycles for patients with FLT3 mutation positive AML, and noted the incremental cost of the additional two doses. In addition, the Subcommittee considered that the available evidence did not support maintenance therapy with midostaurin in this patient population. The Subcommittee considered that it was reasonable to specify a maximum of four cycles of midostaurin with intensive therapy, without maintenance, in the Special Authority criteria based on this assessment.</p><p><br></p>', 'fs': '<h2>Discussion</h2><p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that acute myeloid leukaemia (AML) is a haematopoietic neoplasm involving clonal proliferation of myeloid precursor cells, leading to increased production of immature malignant cells and a reduction in mature myeloid cells. The Subcommittee noted that AML is a highly symptomatic, rapidly progressing disease that results in a variety of systemic consequences (e.g. anaemia, bleeding, and an increased risk of infection) due to bone marrow failure or the presence of AML blasts in the bone marrow, peripheral blood or other organs, with poor overall survival. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients with AML spend a substantial amount of time in hospital for disease management, treatment administration, supportive care and investigations; this inpatient duration may be weeks or months for patients who receive intensive chemotherapy. The Subcommittee noted evidence where the caregivers of patients with AML, in addition to patients themselves, experienced post-traumatic stress (<a href=""https://pubmed.ncbi.nlm.nih.gov/24673368/"" target=""_blank"">Leunis et al. Eur J Haematol. 2014;93:198-206</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/26014209/"" target=""_blank"">Jia et al. Psychooncology. 2015;24:1754-60</a>). Members considered the impact on family and whānau is due to the need to support the patient with AML through this long and difficult illness. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that AML is the most common acute leukaemia diagnosed in New Zealand adults, with incidence estimated to be 6-9 per 100,000 in the population in 2016 (<a href=""https://pubmed.ncbi.nlm.nih.gov/29860482/"" target=""_blank"">Global Burden of Disease Cancer Collaboration. JAMA Oncol. 2018;4:1553-68</a>). However, Members estimated that if AML secondary to prior haematological malignancy or previous treatment of malignant disease is excluded, the incidence of <i>de novo</i> AML in New Zealand is lower, closer to 3.5 per 100,000. The Subcommittee noted that AML incidence increases with age and that the median age at diagnosis is between 65 to 70 years. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that Māori have an increased risk of AML relative to New Zealand Caucasians (<a href=""https://pubmed.ncbi.nlm.nih.gov/15929115/"" target=""_blank"">Tracey et al. Am J Hematol. 2005;79:114-8</a>) and that Māori have reduced chances of finding suitable stem cell donors from international registries, leading to disproportionately less stem cell transplantation as part of therapy for AML.<span style=""background-color: yellow; font-size: 7pt;""> </span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that standard of care diagnostic investigation of patients with AML includes bone marrow sampling, molecular testing and immunophenotyping via flow cytometry; the latter of which would detect the cell surface antigen CD33 that is present for approximately 85–90% of patients with AML. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the health need and probability of survival for patients with AML is predominantly influenced by age and cytogenetic risk profile which can be categorised as favourable or intermediate (combined, these account for about 70% of <i>de novo</i> AML) or as adverse (~30% of cases). The Subcommittee noted that molecular testing identifies a range of genetic mutations in AML which occur in different patterns and combinations, contributing to a patient’s cytogenetic risk: </p><p style=""text-align: justify;"">1.6.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that the FLT3 (FMS-like tyrosine kinase 3) mutation occurs in about one-third of patients with AML. The Subcommittee considered that patients with FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) experience more frequent and earlier disease relapse leading to poor survival.</p><p style=""text-align: justify;"">1.6.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that patients with acute promyelocytic leukaemia (APL) have a particular, mutation, that is associated with good outcomes from current treatment, therefore patients with APL were considered out of scope for the current funding applications. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that cytogenetic testing is routinely available across New Zealand and that results are generally available within 48 to 72 hours. The Subcommittee considered it important for cytogenetic results to be available before treatment commences to ensure therapy is optimal with regard to the patient’s cytogenetics, however, unavoidable delays (e.g. due to public holidays) are known to lead to additional supportive care requirements while results are pending. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that approximately half to three-quarters of younger patients (generally defined as those aged less than 60 years) with AML are suitable for intensive induction and consolidation chemotherapy with anthracycline (e.g. daunorubicin) and cytarabine, both which are currently funded without restriction and remain the backbone of intensive treatment for AML. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that many New Zealand patients with AML have participated in UK-based clinical trials, most recently the AML-19 trial; a randomised, factorial design, open-label, phase III trial comparing several different treatment strategies (including gemtuzumab ozogamicin and midostaurin) in adults with <i>de novo</i> AML who are suitable for intensive chemotherapy. Members considered that early data from the AML-19 trial suggests an improvement in long-term survival in younger patients.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that azacitidine is not used to treat patients with AML who are deemed suitable for treatment with intensive chemotherapy. The Subcommittee considered that azacitidine is generally used in patients of older age, those who are frail, have low AML blast cell counts and have adverse cytogenetics. As a result, the Subcommittee considered that any widening of access to azacitidine for patients with AML would not affect the treatment paradigm for patients with AML who are suitable candidates for intensive chemotherapy.</p><p style=""text-align: justify;""><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that disease relapse, which is accompanied by a return of symptoms due to blast cell re-emergence, is of high unmet clinical need for patients with AML as there are limited subsequent treatment options and often very shortened survival post-relapse. The Subcommittee noted that younger patients with AML who receive intensive treatment have 5 year-survival rates of about 50% at 5 years and this rate has improved over past decades, predominantly driven by improved understanding of the disease, therapeutic approaches and molecular testing in clinical trials; however, patients over 60 have a lower rate of survival (about 25% at 5 years) and this has not improved substantially over past decades.</p><p style=""text-align: justify;""><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>Members noted that patients with AML with intermediate or adverse disease risk that is in remission after intensive chemotherapy treatment may be fit enough to undergo allogenic stem cell transplant, leading to better outcomes for such patients; however, older patients (e.g. patients over 60 years of age) may not be suitable candidates for transplant and therefore are unable to receive this additional benefit.</p><p><br></p><h2>Midostaurin</h2><p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that midostaurin is a multi-targeted kinase inhibitor that inhibits FLT3 receptor signalling, inducing cell death in leukaemic cells that express mutated FLT3 receptors and overexpressed wild-type receptors. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that midostaurin is approved by Medsafe for use in combination with standard anthracycline and cytarabine induction and cytarabine consolidation chemotherapy, followed in patients with complete response by single agent maintenance therapy for adult patients with newly diagnosed AML who are FLT3 mutation-positive. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.3. </span>The Subcommittee noted that midostaurin is available as 25 mg capsule and would be administered in combination with standard intensive chemotherapy containing anthracycline and cytarabine, with midostaurin taken orally at a dose of 50 mg twice daily on days 8 to 21 of each 21-day cycle (14 days of treatment). </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the target patient population for midostaurin (FLT3 mutation positive disease) is a subset of the target patient population for gemtuzumab ozogamicin (AML with favourable or intermediate cytogenetic risk). The Subcommittee noted that the supplier had requested midostaurin be funded for induction and consolidation therapy, and then as maintenance for twelve 28-day cycles, however, the clinician applicants had requested funding for induction and consolidation therapy only. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that the key clinical trial evidence for midostaurin comes from the phase III, randomised (1:1), double-blind, placebo-controlled multicentre RATIFY trial which included 717 patients aged 18 to 59 years with newly diagnosed, untreated AML (excluding APL) with TKD or ITD (high or low) FLT3-mutations (<a href=""https://pubmed.ncbi.nlm.nih.gov/28644114/"" target=""_blank"">Stone et al. N Engl J Med. 2017;377:454-64</a>). The Subcommittee noted that the study investigated standard induction with daunorubicin 60 mg/m<sup>2</sup>, cytarabine 200 mg/m<sup>2</sup> plus midostaurin or placebo; then standard consolidation therapy with high-dose cytarabine 3 g/m<sup>2</sup> twice daily plus midostaurin or placebo; then if in remission, maintenance midostaurin or placebo. Patients received midostaurin 50 mg orally twice daily or placebo taken for a fortnight within each 21-day treatment cycle during induction and consolidation (total of five or six cycles), then midostaurin 50 mg orally twice daily or placebo alone (according to initial randomisation) for twelve 28-day cycles during maintenance therapy. The Subcommittee noted that 36% (896) of patients screened for the RATIFY trial (3,277) had FLT3 mutations and that over half of the patients in each arm received stem cell transplant in the first line of therapy. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that the RATIFY trial reported median event-free survival (EFS) of 8.2 months (95% CI: 5.4 to 10.7) with midostaurin compared with 3.0 months (95% CI: 1.9 to 5.9) with placebo (HR for event 0.78, 95% CI: 0.66 to 0.93, P=0.002). The Subcommittee noted that the median OS in the RATIFY trial was 74.7 months (95% CI: 31.5 to not reached) with midostaurin compared with 25.6 months (95% CI: 18.6 to 42.9) with placebo (HR for death 0.78, 95% CI: 0.63 to 0.96, P=0.009). The Subcommittee considered that this evidence showed a benefit of midostaurin treatment with respect to EFS and OS in patients with AML with FLT3 mutations, and noted that subgroup analysis according to ITD or TKD status reported similar hazard ratios for OS although these were not statistically significant.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the RATIFY trial reported higher rates of grade 3 to 5 anaemia (92.7% with midostaurin compared with 87.8% with placebo, <i>P</i>=0.03) and rash (14.1% with midostaurin compared with 7.6% with placebo, <i>P</i>=0.008). Overall, the Subcommittee considered that the rates of serious adverse events (SAEs) were similar between the groups and that midostaurin was well tolerated, although tolerance was lower in patients who received midostaurin post-transplant. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.8. </span>The Subcommittee noted that the comparative evidence for midostaurin maintenance following intensive chemotherapy came from the RATIFY trial; however, RATIFY participants who received intensive chemotherapy without midostaurin were unable to cross over to receive midostaurin in the maintenance phase, therefore the trial did not provide appropriate evidence indicating additional benefit from the addition of midostaurin as maintenance. The Committee considered that there is currently limited trial evidence of benefit from midostaurin maintenance, and that the ongoing clinical trials would contribute to this understanding. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.9. </span>The Subcommittee noted evidence from the phase II, open-label, hypothesis-generating AMLSG 16-10 trial, which investigated use of midostaurin during induction (50 mg twice daily, starting on day 8, until 48 hours before the start of the subsequent chemotherapy cycle) with daunorubicin 60 mg/m<sup>2 </sup>and cytarabine<sup> </sup>200 mg/m<sup>2</sup>, in consolidation with either allogenic stem cell transplant or high-dose cytarabine 3 g/m<sup>2</sup> (<span style=""color: rgb(26, 26, 26); font-family: Helvetica, sans-serif;"">starting on day 6, until 48 hours before the start of conditioning therapy for stem cell transplant or the start of subsequent consolidation chemotherapy)</span> and as maintenance therapy (midostaurin alone, 50 mg orally twice daily for twelve 28-day cycles) in 284 patients with newly diagnosed AML (including secondary AML but excluding APL) with FLT3-ITD mutation (<a href=""https://pubmed.ncbi.nlm.nih.gov/30563875/"" target=""_blank"">Schlenk et al. Blood. 2019;133:840-51</a>). </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the AMLSG 16-10 trial allowed allogenic transplant at investigator discretion and included patients up to 70 years of age. The Subcommittee noted that the trial used historical controls from five prospective AMLSG trials of induction and consolidation, recruiting from 1993-2008, and considered that these controls were of limited quality for comparison.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that median EFS in AMLSG 16-10 was 13.2 months (95% CI: 10.0-18.3 months), and that EFS at two years was 39% (95% CI: 33-47%) in younger patients aged 18 to 60 years and 53% (95% CI: 46-61%) in older patients aged 61 to 70 years. The Subcommittee noted that median OS was 26.0 months (95% CI: 18.9-37.0 months) and that OS at 2 years was 34% (95% CI: 24-47%) in younger patients and 46% (95% CI: 35-59%) in older patients. The Subcommittee considered that midostaurin provided good outcomes for patients aged over 60.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted additional evidence provided by the supplier regarding midostaurin in AML, including the following from phase I-IIb clinical trials:</p><p style=""text-align: justify;""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/25776192/"" target=""_blank"">Cooper et al. Clin Lymphoma Myeloma Leuk. 2015;15:428-32</a> </p><p style=""text-align: justify;""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/22627678"" target=""_blank"">Stone et al. Leukaemia. 2012;26:2061-8</a> </p><p style=""text-align: justify;""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/20733134"" target=""_blank"">Fischer et al. J Clin Oncol. 2010;28:4339-45</a> </p><p style=""text-align: justify;""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/25530214"" target=""_blank"">Strati et al. Am J Hematol. 2015;90:276-81</a></p><p style=""text-align: justify;""><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee considered that approximately 88 patients with AML would be fit for intensive chemotherapy each year in New Zealand, of which approximately three-quarters (66 patients) would have favourable or intermediate cytogenetics (and would therefore be potentially suitable for gemtuzumab ozogamicin); approximately one third of those patients would have mutation in FLT3 that would make them potentially suitable for treatment with midostaurin.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee considered that midostaurin would provide a treatment benefit for the group of patients with AML with favourable or intermediate cytogenetic risk who have FLT3 mutation positive disease. The Subcommittee considered that the use of midostaurin, if funded, would not change usage of other funded medicines used to treat AML. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;""> </span>Members considered that there is no evidence to suggest that patients with AML have an unmet need for maintenance treatment after intensive chemotherapy or as a bridge to transplant, noting that transplant requires disease remission and the current evidence indicates that neither maintenance therapy or treatment used as a bridge to transplant improves remission rates in AML.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;""> </span>\xa0The Subcommittee considered that, based on the mature published evidence for midostaurin at this time, four cycles of midostaurin given with intensive chemotherapy would provide sufficient survival benefit compared with six cycles for patients with FLT3 mutation positive AML, and noted the incremental cost of the additional two doses. In addition, the Subcommittee considered that the available evidence did not support maintenance therapy with midostaurin in this patient population. The Subcommittee considered that it was reasonable to specify a maximum of four cycles of midostaurin with intensive therapy, without maintenance, in the Special Authority criteria based on this assessment.</p><p><br></p>', 'change': None}, 'Published_Application': {'s': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee considered the following applications for midostaurin:</p><p style=""text-align: justify;"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Clinician applications for midostaurin for the treatment of patients with AML, submitted on behalf of the New Zealand Branch of the Haematology Society of Australia and New Zealand and the National New Zealand Haematology Trials Group; and</p><p style=""text-align: justify;"">1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>A supporting supplier application from Novartis for midostaurin (Rydapt), received in February 2020, for the treatment of newly diagnosed FLT3-mutation positive AML, considered eligible for standard intensive remission induction and consolidation therapy, and as monotherapy maintenance for eligible patients.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0 </span>The Subcommittee also noted that in April 2020, PHARMAC received multiple letters of support from clinicians at District Health Boards (DHBs) across New Zealand regarding the funding applications for gemtuzumab ozogamicin and midostaurin.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.3. </span>The Subcommittee noted that, the clinician applications for gemtuzumab ozogamicin and midostaurin refer to patients with acute myeloid leukaemia (AML) and in addition, those who may participate in the UK Medical Research Council (MRC) AML-19 clinical trial. The Subcommittee considered the above applications for gemtuzumab ozogamicin and midostaurin for listing on the Pharmaceutical Schedule for the treatment of AML, irrespective of clinical trial participation.</p><p><br></p>', 'fs': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee considered the following applications for midostaurin:</p><p style=""text-align: justify;"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Clinician applications for midostaurin for the treatment of patients with AML, submitted on behalf of the New Zealand Branch of the Haematology Society of Australia and New Zealand and the National New Zealand Haematology Trials Group; and</p><p style=""text-align: justify;"">1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>A supporting supplier application from Novartis for midostaurin (Rydapt), received in February 2020, for the treatment of newly diagnosed FLT3-mutation positive AML, considered eligible for standard intensive remission induction and consolidation therapy, and as monotherapy maintenance for eligible patients.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0 </span>The Subcommittee also noted that in April 2020, PHARMAC received multiple letters of support from clinicians at District Health Boards (DHBs) across New Zealand regarding the funding applications for gemtuzumab ozogamicin and midostaurin.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.3. </span>The Subcommittee noted that, the clinician applications for gemtuzumab ozogamicin and midostaurin refer to patients with acute myeloid leukaemia (AML) and in addition, those who may participate in the UK Medical Research Council (MRC) AML-19 clinical trial. The Subcommittee considered the above applications for gemtuzumab ozogamicin and midostaurin for listing on the Pharmaceutical Schedule for the treatment of AML, irrespective of clinical trial participation.</p><p><br></p>', 'change': None}, 'PTAC_Comments': {'s': '<p>At the August 2020 of PTAC The Committee</p><p><br></p><p>The Committee noted that Māori have an increased prevalence and risk of AML compared to New Zealand Caucasians.</p><p><br></p><p>The Committee noted the Subcommittee’s recommendation to fund gemtuzumab-ozogamicin with a high priority and acknowledged CaTSoP’s discussion of gemtuzumab-ozogamicin for the treatment of patients with favourable and intermediate cytogenetic risk AML.</p><p><br></p><p>The Committee noted the results of the ALFA-0701 trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/30076173"" target=""_blank"">Lambert et al. Haematologica. 2019;104:113-9</a>) and the Hills et al. meta analysis (<a href=""https://pubmed.ncbi.nlm.nih.gov/25008258/"" target=""_blank"">Hills et al. Lancet Oncol. 2014;15:986-96</a>) which indicated an event free survival improvement for gemtuzumab-ozogamicin compared with standard chemotherapy for the treatment of patients with intermediate or favourable cytogenetic risk AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for gemtuzumab-ozogamicin compared with standard chemotherapy in this population.</p><p><br></p><p>The Committee noted the Subcommittee’s recommendation to fund midostaurin with a high priority and acknowledged CaTSoP’s discussion of midostaurin for the treatment of patients with FLT3 mutation positive AML</p><p><br></p><p>The Committee noted the results of the RATIFY trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/28644114/"" target=""_blank"">Stone et al. N Engl J Med. 2017;377:454-64</a>) which indicated an event free survival improvement for midostaurin compared with standard chemotherapy for the treatment of patients with FLT3 mutation positive AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for midostaurin compared to the standard chemotherapy for the treatment of FLT3 mutation positive AML.</p><p><br></p><p>The Committee considered that based on the available evidence that there was a greater survival benefit for midostaurin than that of gemtuzumab-ozogamicin. However, the Committee noted the higher relative priority consideration by CaTSoP for gemtuzumab-ozogamicin compared to midostaurin on the basis that gemtuzumab ozogamicin would result in benefits for a wider population of patients with AML.\xa0</p><p><br></p><p><br></p>', 'fs': '<p>At the August 2020 of PTAC The Committee</p><p><br></p><p>The Committee noted that Māori have an increased prevalence and risk of AML compared to New Zealand Caucasians.</p><p><br></p><p>The Committee noted the Subcommittee’s recommendation to fund gemtuzumab-ozogamicin with a high priority and acknowledged CaTSoP’s discussion of gemtuzumab-ozogamicin for the treatment of patients with favourable and intermediate cytogenetic risk AML.</p><p><br></p><p>The Committee noted the results of the ALFA-0701 trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/30076173"" target=""_blank"">Lambert et al. Haematologica. 2019;104:113-9</a>) and the Hills et al. meta analysis (<a href=""https://pubmed.ncbi.nlm.nih.gov/25008258/"" target=""_blank"">Hills et al. Lancet Oncol. 2014;15:986-96</a>) which indicated an event free survival improvement for gemtuzumab-ozogamicin compared with standard chemotherapy for the treatment of patients with intermediate or favourable cytogenetic risk AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for gemtuzumab-ozogamicin compared with standard chemotherapy in this population.</p><p><br></p><p>The Committee noted the Subcommittee’s recommendation to fund midostaurin with a high priority and acknowledged CaTSoP’s discussion of midostaurin for the treatment of patients with FLT3 mutation positive AML</p><p><br></p><p>The Committee noted the results of the RATIFY trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/28644114/"" target=""_blank"">Stone et al. N Engl J Med. 2017;377:454-64</a>) which indicated an event free survival improvement for midostaurin compared with standard chemotherapy for the treatment of patients with FLT3 mutation positive AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for midostaurin compared to the standard chemotherapy for the treatment of FLT3 mutation positive AML.</p><p><br></p><p>The Committee considered that based on the available evidence that there was a greater survival benefit for midostaurin than that of gemtuzumab-ozogamicin. However, the Committee noted the higher relative priority consideration by CaTSoP for gemtuzumab-ozogamicin compared to midostaurin on the basis that gemtuzumab ozogamicin would result in benefits for a wider population of patients with AML.\xa0</p><p><br></p><p><br></p>', 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2020', 'fs': 'Sep 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 3 July 2020.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 3 July 2020.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005fBfu2AE'}, 'Id': 'a0POZ000005fBfu2AE', 'Event_Date__c': '2020-09-29', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 3 July 2020.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Sep 2020', 'Published_Recommendation__c': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee <b>recommended</b> that midostaurin (up to four cycles with intensive chemotherapy, without maintenance therapy) be funded for the treatment of <i>de novo</i> acute myeloid leukaemia that is FLT3 mutation positive with a high priority within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application — only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a diagnosis of acute myeloid leukaemia; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Condition must be FMS tyrosine kinase 3 (FLT3) mutation positive; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must not have received a prior line of intensive chemotherapy for acute myeloid leukaemia; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be considered eligible for standard intensive chemotherapy; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Midostaurin to be funded for a maximum of 4 cycles.</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee noted that the supplier of midostaurin had requested funding for up to six cycles with intensive chemotherapy and funding for up to 12 cycles of maintenance therapy. However, the Subcommittee considered that the incremental benefit of six cycles of midostaurin over four cycles in combination with intensive chemotherapy was not sufficient to warrant the additional two cycles, and that the available evidence did not support a benefit of midostaurin maintenance in this patient population.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee also considered that, if PHARMAC was only able to fund one of these medicines (i.e gemtuzumab ozogamicin or midostaurin) for the treatment of patients with favourable, intermediate or undetermined risk AML, the greater clinical benefit could be obtained through first funding gemtuzumab ozogamicin, as this would result in benefits for a wider population rather than a defined subset of the population.</p><p><br></p>', 'Published_Application__c': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee considered the following applications for midostaurin:</p><p style=""text-align: justify;"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Clinician applications for midostaurin for the treatment of patients with AML, submitted on behalf of the New Zealand Branch of the Haematology Society of Australia and New Zealand and the National New Zealand Haematology Trials Group; and</p><p style=""text-align: justify;"">1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>A supporting supplier application from Novartis for midostaurin (Rydapt), received in February 2020, for the treatment of newly diagnosed FLT3-mutation positive AML, considered eligible for standard intensive remission induction and consolidation therapy, and as monotherapy maintenance for eligible patients.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0 </span>The Subcommittee also noted that in April 2020, PHARMAC received multiple letters of support from clinicians at District Health Boards (DHBs) across New Zealand regarding the funding applications for gemtuzumab ozogamicin and midostaurin.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.3. </span>The Subcommittee noted that, the clinician applications for gemtuzumab ozogamicin and midostaurin refer to patients with acute myeloid leukaemia (AML) and in addition, those who may participate in the UK Medical Research Council (MRC) AML-19 clinical trial. The Subcommittee considered the above applications for gemtuzumab ozogamicin and midostaurin for listing on the Pharmaceutical Schedule for the treatment of AML, irrespective of clinical trial participation.</p><p><br></p>', 'Published_Discussion__c': '<h2>Discussion</h2><p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that acute myeloid leukaemia (AML) is a haematopoietic neoplasm involving clonal proliferation of myeloid precursor cells, leading to increased production of immature malignant cells and a reduction in mature myeloid cells. The Subcommittee noted that AML is a highly symptomatic, rapidly progressing disease that results in a variety of systemic consequences (e.g. anaemia, bleeding, and an increased risk of infection) due to bone marrow failure or the presence of AML blasts in the bone marrow, peripheral blood or other organs, with poor overall survival. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients with AML spend a substantial amount of time in hospital for disease management, treatment administration, supportive care and investigations; this inpatient duration may be weeks or months for patients who receive intensive chemotherapy. The Subcommittee noted evidence where the caregivers of patients with AML, in addition to patients themselves, experienced post-traumatic stress (<a href=""https://pubmed.ncbi.nlm.nih.gov/24673368/"" target=""_blank"">Leunis et al. Eur J Haematol. 2014;93:198-206</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/26014209/"" target=""_blank"">Jia et al. Psychooncology. 2015;24:1754-60</a>). Members considered the impact on family and whānau is due to the need to support the patient with AML through this long and difficult illness. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that AML is the most common acute leukaemia diagnosed in New Zealand adults, with incidence estimated to be 6-9 per 100,000 in the population in 2016 (<a href=""https://pubmed.ncbi.nlm.nih.gov/29860482/"" target=""_blank"">Global Burden of Disease Cancer Collaboration. JAMA Oncol. 2018;4:1553-68</a>). However, Members estimated that if AML secondary to prior haematological malignancy or previous treatment of malignant disease is excluded, the incidence of <i>de novo</i> AML in New Zealand is lower, closer to 3.5 per 100,000. The Subcommittee noted that AML incidence increases with age and that the median age at diagnosis is between 65 to 70 years. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that Māori have an increased risk of AML relative to New Zealand Caucasians (<a href=""https://pubmed.ncbi.nlm.nih.gov/15929115/"" target=""_blank"">Tracey et al. Am J Hematol. 2005;79:114-8</a>) and that Māori have reduced chances of finding suitable stem cell donors from international registries, leading to disproportionately less stem cell transplantation as part of therapy for AML.<span style=""background-color: yellow; font-size: 7pt;""> </span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that standard of care diagnostic investigation of patients with AML includes bone marrow sampling, molecular testing and immunophenotyping via flow cytometry; the latter of which would detect the cell surface antigen CD33 that is present for approximately 85–90% of patients with AML. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the health need and probability of survival for patients with AML is predominantly influenced by age and cytogenetic risk profile which can be categorised as favourable or intermediate (combined, these account for about 70% of <i>de novo</i> AML) or as adverse (~30% of cases). The Subcommittee noted that molecular testing identifies a range of genetic mutations in AML which occur in different patterns and combinations, contributing to a patient’s cytogenetic risk: </p><p style=""text-align: justify;"">1.6.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that the FLT3 (FMS-like tyrosine kinase 3) mutation occurs in about one-third of patients with AML. The Subcommittee considered that patients with FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) experience more frequent and earlier disease relapse leading to poor survival.</p><p style=""text-align: justify;"">1.6.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that patients with acute promyelocytic leukaemia (APL) have a particular, mutation, that is associated with good outcomes from current treatment, therefore patients with APL were considered out of scope for the current funding applications. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that cytogenetic testing is routinely available across New Zealand and that results are generally available within 48 to 72 hours. The Subcommittee considered it important for cytogenetic results to be available before treatment commences to ensure therapy is optimal with regard to the patient’s cytogenetics, however, unavoidable delays (e.g. due to public holidays) are known to lead to additional supportive care requirements while results are pending. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that approximately half to three-quarters of younger patients (generally defined as those aged less than 60 years) with AML are suitable for intensive induction and consolidation chemotherapy with anthracycline (e.g. daunorubicin) and cytarabine, both which are currently funded without restriction and remain the backbone of intensive treatment for AML. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that many New Zealand patients with AML have participated in UK-based clinical trials, most recently the AML-19 trial; a randomised, factorial design, open-label, phase III trial comparing several different treatment strategies (including gemtuzumab ozogamicin and midostaurin) in adults with <i>de novo</i> AML who are suitable for intensive chemotherapy. Members considered that early data from the AML-19 trial suggests an improvement in long-term survival in younger patients.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that azacitidine is not used to treat patients with AML who are deemed suitable for treatment with intensive chemotherapy. The Subcommittee considered that azacitidine is generally used in patients of older age, those who are frail, have low AML blast cell counts and have adverse cytogenetics. As a result, the Subcommittee considered that any widening of access to azacitidine for patients with AML would not affect the treatment paradigm for patients with AML who are suitable candidates for intensive chemotherapy.</p><p style=""text-align: justify;""><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that disease relapse, which is accompanied by a return of symptoms due to blast cell re-emergence, is of high unmet clinical need for patients with AML as there are limited subsequent treatment options and often very shortened survival post-relapse. The Subcommittee noted that younger patients with AML who receive intensive treatment have 5 year-survival rates of about 50% at 5 years and this rate has improved over past decades, predominantly driven by improved understanding of the disease, therapeutic approaches and molecular testing in clinical trials; however, patients over 60 have a lower rate of survival (about 25% at 5 years) and this has not improved substantially over past decades.</p><p style=""text-align: justify;""><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>Members noted that patients with AML with intermediate or adverse disease risk that is in remission after intensive chemotherapy treatment may be fit enough to undergo allogenic stem cell transplant, leading to better outcomes for such patients; however, older patients (e.g. patients over 60 years of age) may not be suitable candidates for transplant and therefore are unable to receive this additional benefit.</p><p><br></p><h2>Midostaurin</h2><p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that midostaurin is a multi-targeted kinase inhibitor that inhibits FLT3 receptor signalling, inducing cell death in leukaemic cells that express mutated FLT3 receptors and overexpressed wild-type receptors. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that midostaurin is approved by Medsafe for use in combination with standard anthracycline and cytarabine induction and cytarabine consolidation chemotherapy, followed in patients with complete response by single agent maintenance therapy for adult patients with newly diagnosed AML who are FLT3 mutation-positive. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.3. </span>The Subcommittee noted that midostaurin is available as 25 mg capsule and would be administered in combination with standard intensive chemotherapy containing anthracycline and cytarabine, with midostaurin taken orally at a dose of 50 mg twice daily on days 8 to 21 of each 21-day cycle (14 days of treatment). </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the target patient population for midostaurin (FLT3 mutation positive disease) is a subset of the target patient population for gemtuzumab ozogamicin (AML with favourable or intermediate cytogenetic risk). The Subcommittee noted that the supplier had requested midostaurin be funded for induction and consolidation therapy, and then as maintenance for twelve 28-day cycles, however, the clinician applicants had requested funding for induction and consolidation therapy only. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that the key clinical trial evidence for midostaurin comes from the phase III, randomised (1:1), double-blind, placebo-controlled multicentre RATIFY trial which included 717 patients aged 18 to 59 years with newly diagnosed, untreated AML (excluding APL) with TKD or ITD (high or low) FLT3-mutations (<a href=""https://pubmed.ncbi.nlm.nih.gov/28644114/"" target=""_blank"">Stone et al. N Engl J Med. 2017;377:454-64</a>). The Subcommittee noted that the study investigated standard induction with daunorubicin 60 mg/m<sup>2</sup>, cytarabine 200 mg/m<sup>2</sup> plus midostaurin or placebo; then standard consolidation therapy with high-dose cytarabine 3 g/m<sup>2</sup> twice daily plus midostaurin or placebo; then if in remission, maintenance midostaurin or placebo. Patients received midostaurin 50 mg orally twice daily or placebo taken for a fortnight within each 21-day treatment cycle during induction and consolidation (total of five or six cycles), then midostaurin 50 mg orally twice daily or placebo alone (according to initial randomisation) for twelve 28-day cycles during maintenance therapy. The Subcommittee noted that 36% (896) of patients screened for the RATIFY trial (3,277) had FLT3 mutations and that over half of the patients in each arm received stem cell transplant in the first line of therapy. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that the RATIFY trial reported median event-free survival (EFS) of 8.2 months (95% CI: 5.4 to 10.7) with midostaurin compared with 3.0 months (95% CI: 1.9 to 5.9) with placebo (HR for event 0.78, 95% CI: 0.66 to 0.93, P=0.002). The Subcommittee noted that the median OS in the RATIFY trial was 74.7 months (95% CI: 31.5 to not reached) with midostaurin compared with 25.6 months (95% CI: 18.6 to 42.9) with placebo (HR for death 0.78, 95% CI: 0.63 to 0.96, P=0.009). The Subcommittee considered that this evidence showed a benefit of midostaurin treatment with respect to EFS and OS in patients with AML with FLT3 mutations, and noted that subgroup analysis according to ITD or TKD status reported similar hazard ratios for OS although these were not statistically significant.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the RATIFY trial reported higher rates of grade 3 to 5 anaemia (92.7% with midostaurin compared with 87.8% with placebo, <i>P</i>=0.03) and rash (14.1% with midostaurin compared with 7.6% with placebo, <i>P</i>=0.008). Overall, the Subcommittee considered that the rates of serious adverse events (SAEs) were similar between the groups and that midostaurin was well tolerated, although tolerance was lower in patients who received midostaurin post-transplant. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.8. </span>The Subcommittee noted that the comparative evidence for midostaurin maintenance following intensive chemotherapy came from the RATIFY trial; however, RATIFY participants who received intensive chemotherapy without midostaurin were unable to cross over to receive midostaurin in the maintenance phase, therefore the trial did not provide appropriate evidence indicating additional benefit from the addition of midostaurin as maintenance. The Committee considered that there is currently limited trial evidence of benefit from midostaurin maintenance, and that the ongoing clinical trials would contribute to this understanding. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.9. </span>The Subcommittee noted evidence from the phase II, open-label, hypothesis-generating AMLSG 16-10 trial, which investigated use of midostaurin during induction (50 mg twice daily, starting on day 8, until 48 hours before the start of the subsequent chemotherapy cycle) with daunorubicin 60 mg/m<sup>2 </sup>and cytarabine<sup> </sup>200 mg/m<sup>2</sup>, in consolidation with either allogenic stem cell transplant or high-dose cytarabine 3 g/m<sup>2</sup> (<span style=""color: rgb(26, 26, 26); font-family: Helvetica, sans-serif;"">starting on day 6, until 48 hours before the start of conditioning therapy for stem cell transplant or the start of subsequent consolidation chemotherapy)</span> and as maintenance therapy (midostaurin alone, 50 mg orally twice daily for twelve 28-day cycles) in 284 patients with newly diagnosed AML (including secondary AML but excluding APL) with FLT3-ITD mutation (<a href=""https://pubmed.ncbi.nlm.nih.gov/30563875/"" target=""_blank"">Schlenk et al. Blood. 2019;133:840-51</a>). </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the AMLSG 16-10 trial allowed allogenic transplant at investigator discretion and included patients up to 70 years of age. The Subcommittee noted that the trial used historical controls from five prospective AMLSG trials of induction and consolidation, recruiting from 1993-2008, and considered that these controls were of limited quality for comparison.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that median EFS in AMLSG 16-10 was 13.2 months (95% CI: 10.0-18.3 months), and that EFS at two years was 39% (95% CI: 33-47%) in younger patients aged 18 to 60 years and 53% (95% CI: 46-61%) in older patients aged 61 to 70 years. The Subcommittee noted that median OS was 26.0 months (95% CI: 18.9-37.0 months) and that OS at 2 years was 34% (95% CI: 24-47%) in younger patients and 46% (95% CI: 35-59%) in older patients. The Subcommittee considered that midostaurin provided good outcomes for patients aged over 60.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted additional evidence provided by the supplier regarding midostaurin in AML, including the following from phase I-IIb clinical trials:</p><p style=""text-align: justify;""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/25776192/"" target=""_blank"">Cooper et al. Clin Lymphoma Myeloma Leuk. 2015;15:428-32</a> </p><p style=""text-align: justify;""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/22627678"" target=""_blank"">Stone et al. Leukaemia. 2012;26:2061-8</a> </p><p style=""text-align: justify;""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/20733134"" target=""_blank"">Fischer et al. J Clin Oncol. 2010;28:4339-45</a> </p><p style=""text-align: justify;""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/25530214"" target=""_blank"">Strati et al. Am J Hematol. 2015;90:276-81</a></p><p style=""text-align: justify;""><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee considered that approximately 88 patients with AML would be fit for intensive chemotherapy each year in New Zealand, of which approximately three-quarters (66 patients) would have favourable or intermediate cytogenetics (and would therefore be potentially suitable for gemtuzumab ozogamicin); approximately one third of those patients would have mutation in FLT3 that would make them potentially suitable for treatment with midostaurin.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee considered that midostaurin would provide a treatment benefit for the group of patients with AML with favourable or intermediate cytogenetic risk who have FLT3 mutation positive disease. The Subcommittee considered that the use of midostaurin, if funded, would not change usage of other funded medicines used to treat AML. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;""> </span>Members considered that there is no evidence to suggest that patients with AML have an unmet need for maintenance treatment after intensive chemotherapy or as a bridge to transplant, noting that transplant requires disease remission and the current evidence indicates that neither maintenance therapy or treatment used as a bridge to transplant improves remission rates in AML.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;""> </span>\xa0The Subcommittee considered that, based on the mature published evidence for midostaurin at this time, four cycles of midostaurin given with intensive chemotherapy would provide sufficient survival benefit compared with six cycles for patients with FLT3 mutation positive AML, and noted the incremental cost of the additional two doses. In addition, the Subcommittee considered that the available evidence did not support maintenance therapy with midostaurin in this patient population. The Subcommittee considered that it was reasonable to specify a maximum of four cycles of midostaurin with intensive therapy, without maintenance, in the Special Authority criteria based on this assessment.</p><p><br></p>', 'PTAC_Comments__c': '<p>At the August 2020 of PTAC The Committee</p><p><br></p><p>The Committee noted that Māori have an increased prevalence and risk of AML compared to New Zealand Caucasians.</p><p><br></p><p>The Committee noted the Subcommittee’s recommendation to fund gemtuzumab-ozogamicin with a high priority and acknowledged CaTSoP’s discussion of gemtuzumab-ozogamicin for the treatment of patients with favourable and intermediate cytogenetic risk AML.</p><p><br></p><p>The Committee noted the results of the ALFA-0701 trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/30076173"" target=""_blank"">Lambert et al. Haematologica. 2019;104:113-9</a>) and the Hills et al. meta analysis (<a href=""https://pubmed.ncbi.nlm.nih.gov/25008258/"" target=""_blank"">Hills et al. Lancet Oncol. 2014;15:986-96</a>) which indicated an event free survival improvement for gemtuzumab-ozogamicin compared with standard chemotherapy for the treatment of patients with intermediate or favourable cytogenetic risk AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for gemtuzumab-ozogamicin compared with standard chemotherapy in this population.</p><p><br></p><p>The Committee noted the Subcommittee’s recommendation to fund midostaurin with a high priority and acknowledged CaTSoP’s discussion of midostaurin for the treatment of patients with FLT3 mutation positive AML</p><p><br></p><p>The Committee noted the results of the RATIFY trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/28644114/"" target=""_blank"">Stone et al. N Engl J Med. 2017;377:454-64</a>) which indicated an event free survival improvement for midostaurin compared with standard chemotherapy for the treatment of patients with FLT3 mutation positive AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for midostaurin compared to the standard chemotherapy for the treatment of FLT3 mutation positive AML.</p><p><br></p><p>The Committee considered that based on the available evidence that there was a greater survival benefit for midostaurin than that of gemtuzumab-ozogamicin. However, the Committee noted the higher relative priority consideration by CaTSoP for gemtuzumab-ozogamicin compared to midostaurin on the basis that gemtuzumab ozogamicin would result in benefits for a wider population of patients with AML.\xa0</p><p><br></p><p><br></p>', 'Status_History__c': 'a132P000000CDByQAO'}, 'change': None}]",Mar 2020,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2020', 'fs': 'Nov 2020', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005fBfv2AE'}, 'Id': 'a0POZ000005fBfv2AE', 'Event_Date__c': '2020-11-24', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Nov 2020', 'Status_History__c': 'a132P000000CNQxQAO'}, 'change': None}]",Nov 2020,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2020', 'fs': 'Dec 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005fBfw2AE'}, 'Id': 'a0POZ000005fBfw2AE', 'Event_Date__c': '2020-12-16', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2020', 'Status_History__c': 'a132P000000CSGpQAO'}, 'change': None}]",Dec 2020,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005fBfx2AE'}, 'Id': 'a0POZ000005fBfx2AE', 'Event_Date__c': '2023-12-12', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000006DLjzYAG'}, 'change': None}]",Dec 2023,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2024', 'fs': 'Jan 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005fBfy2AE'}, 'Id': 'a0POZ000005fBfy2AE', 'Event_Date__c': '2024-01-10', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Jan 2024', 'Status_History__c': 'a13OZ000006DeM3YAK'}, 'change': None}]",Jan 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-fund-treatments-for-breast-cancer-and-leukaemia', 'fs': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-fund-treatments-for-breast-cancer-and-leukaemia', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2024', 'fs': 'Feb 2024', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000005fBfz2AE'}, 'Id': 'a0POZ000005fBfz2AE', 'Event_Date__c': '2024-02-26', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Summary__c': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-fund-treatments-for-breast-cancer-and-leukaemia', 'Formatted_Date__c': 'Feb 2024', 'Status_History__c': 'a13OZ000007IJhiYAG'}, 'change': None}]",Feb 2024,False,True
